

CUIMC Research Pharmacy

Milstein Hospital Building 177 Fort Washington Avenue, Suite MHB-LL1-001 New York, NY 10032 212.305.9867 Tel 212.305.0068 Fax

COST ESTIMATE REQUEST FORM

Please complete the entire form so the Research Pharmacy may provide you with a cost estimate.

Return the completed form to researchpharmacy@columbia.edu as an e-mail attachment.

Include a copy of the protocol if not submitted prior.

Please allow up to 2 weeks for the review process. This time may be longer if Research Pharmacy is waiting for clarification from the study team or sponsor.

IRB #	(if available)		
Contact Information:			
Investigator:	Phone:		
Fax:	E-mail:		
Coordinator:	Phone:		
Fax:	E-mail:		
Administrator:	Phone:		
	E-mail:		
Important: If the listed "Administrator" point of contact for the "Principal Investigations of the "Principal Investigations of the Investigation of the Inv	s to serve as point-of-contact for receiving study invoices and billing information, please list this same igator Designee"		
Study Title:			
Study Description: (check	all that apply) □ Inpatient □Outpatient □Multicenter		
On Call Study: □Yes [□No Weekend or Holiday dispensing? □Yes □No		
	n call if there is a possibility for dispensing outside of normal business nd Observed Holidays. There is an additional fee for this service. ***		

CONFIDENTIAL Page 1 REVISED 07/01/2024

Department:

	Biochemistry & Molecular Biophysics		Pediatrics - Allergy
	Biomedical Informatics		Pediatrics - Biomathematics
	Dental Medicine		Pediatrics - BMT
	Dermatology		Pediatrics - Cardiology
	Genetics & Development		Pediatrics - Clinical Genetics
	Medicine - Cardiology		Pediatrics - Critical Care
	Medicine - Digestive & Liver Disease		Pediatrics - Education
	Medicine - Endocrinology		Pediatrics - Emergency Med
	Medicine - Experimental Therapeutics		Pediatrics - Endocrinology
	Medicine - General Medicine		Pediatrics – Gastroent. & Nutrition
	Medicine - Hematology		Pediatrics - General
	Medicine - Infectious Disease		Pediatrics - Hematology
	Medicine - Molecular Medicine		Pediatrics – Infectious Disease
	Medicine - Nephrology		Pediatrics – Molecular Genetics
	Medicine - Oncology		Pediatrics - Neonatology
	Medicine - Preventive Medicine & Nutrition		Pediatrics - Nephrology
	Medicine - Pulmonary, Allergy & Critical Care		Pediatrics - Neurology
	Medicine - Rheumatology		Pediatrics - Oncology
	Microbiology & Immunology		Pediatrics - Pulmonary
	Neurology		Pediatrics - Rheumatology
	Neuroscience		Pharmacology
	Neurosurgery		Physiology and Cellular Biophysics
	Obstetrics and Gynecology		Psychiatry
	Ophthalmology		Mailman School of Public Health
	Orthopedic Surgery		Radiation Oncology
	Otolaryngology / Head & Neck Surgery		Rehabilitation Medicine
	Pathology		
	Anesthesiology		Urology
	ICAP		
	Columbia Center for Translational Immunology		Herbert Irving Comprehensive Cancer Center
Fu	nding Source:		
Sp	onsor: ☐ Investigator Initiated ☐ NCI ☐SWOC	3 🗆 (CCG □COG
	Pharmaceutical Industry Sponsored:		
ш.	narmaceattear maustry oponsorea.		
Spo	on NameSpon Pro	t #	
C	Control Name		
spo	on ContactNamePhone		
Fax	k:E-mail:		
	·		

Services requested: (check all that apply)
Dispense: ☐ Capsules/Tablet ☐ Patient Kit ☐ IV Product ☐ Pre-filled Syringes
□Ointment/Cream □Other
Delivery: (Delivery service only available for Oncology studies or On-Call Services) Are deliveries to hospital or clinic sites required? □ Yes □ No
If yes, specify delivery location(s) (Building, Flr, Rm)
Where will patients be seen (Clinic location)?
Drug Product Ordering: □Yes □ No (If YES, complete Study Drugs requested to be purchased and dispensed by Research Pharmacy on next page)
Drug Returns: (Investigator, if unsure, check with study sponsor): Used drug supplies will be returned to Research Pharmacy for immediate destruction
Inventory: Inventory will be handled by the Research Pharmacy using standard GCP compliant methods
Randomization: ☐There is no randomization
□Randomization will be managed by the Investigator and the Research Pharmacy will be notified of treatment assignment in writing on drug order or via separate FAX
□Randomization will be managed by the Research Pharmacy via an Interactive Voice Recognition System (IVRS)
□Randomization will be generated by the sponsor or Investigator and managed by the Research Pharmacy via paper copy or on-line randomization method

<u>Drug Description:</u> Anti-Neoplastic Agent(s)? \square Yes \square No			
Study Drugs: (include all agents that are to be dispensed by Research Pharmacy in the study)			
Study drug provider:			
Formulation: (check all that apply)			
□Capsules □Tablet □Vials □Pre-Packaged For Dispensing			
□Bulk (Requires Packaging/Labeling/Dispensing)			
Storage: (check all that apply)			
\square Room temp \square 2-8°C \square < -10°C \square < -70°C \square Other			
Study Drugs requested to be <u>purchased and dispensed</u> by Research Pharmacy: (include investigational agents & FDA approved drugs that are to be <u>purchased</u> and <u>dispensed</u> by the pharmacy)			
NOTE: Research Pharmacy-sourced investigational agents or FDA approve drugs are not subject to returns; this includes any expired/unused supply that is purchased or sourced by Research Pharmacy for a study.			
Study team acknowledgment regarding Research Pharmacy drug purchase: As part of the Cost Estimate agreement, if the CUIMC Research Pharmacy agrees to procure drug(s) for the conduct of a trial, it is done so with the understanding that the sponsor & the study team agree & acknowledge:			
DRUG PROCUREMENT by RESEARCH PHARMACY memo (page 5)			
Select if memo has been read & acknowledged? YES NO			
Study drug(s) & FDA approved agents to be sourced via Standard of Care: (include study agents that will be sourced & dispensed as standard of care by NYP Hospital & not through Research Pharmacy)			

Additional Items / Equipment Required Notice:
Research Pharmacy only dispenses research medications. All ancillary supplies such as needles, IV pumps, pill cutters, oral syringes, etc. must be provided by the sponsor or purchased by the study team. All these items are to be stored & handled by the study team.



College of Physicians and Surgeons

In affiliation with NewYork-Presbyterian Hospital RESEARCH PHARMACY

Clinical Trials Office 177 Fort Washington Ave, Suite MHB-LL1-001 New York, NY 10032 212.305.9867 Tel researchpharmacy@columbia.edu

March 1st, 2024

Re: Drug Procurement by Research Pharmacy

To Whom It May Concern:

The CUIMC Research Pharmacy (RP) is an investigational drug service established solely to serve the research needs of Columbia's investigators. As such, the RP does not maintain commercial stock of any pharmaceuticals, and any medication necessary for research will need to be provided or otherwise procured. When medications are procured by the RP, it is done so for that specific trial.

Our strong preference is for Sponsors to provide any medication that is required for the conduct of research, including any commercially available medication that is expected to be dispensed by the RP. If the RP agrees to procure drug(s) for the conduct of a trial, as confirmed as part of the Research Pharmacy Cost Estimate agreement/process with the Columbia research team, the agreement is done so with the understanding that the Sponsor and the research team agree and acknowledge the following:

- a. Drugs may only be available in bulk volume and can only be purchased in the package sizes that are available. As a result, some drugs may not be utilized by the study and the RP and Columbia must be reimbursed for the full cost of drug purchased.
- b. Prices are subject to change based on the cost, on the day of purchase. The RP will procure drug based on the research need, regardless of the price, and the RP and Columbia must be reimbursed for the full cost of drug purchased.
- c. Availability is subject to change based on the distributor's inventory, and it may be affected during supply shortage.
- d. The RP will procure drug based on the research need, with the understanding that enough supply must be procured for subjects to ensure site does not come across protocol compliance and shortage issues throughout the course of the trial. The RP and Columbia must be reimbursed for the full cost of all drugs purchased. For example: 1. Drugs may need to be procured prior to randomization and depending on the randomization, drug may not be utilized. 2. Drug may need to be procured in advance of multiple visits and depending on if the patient visits occur, drug may not be utilized.
- e. Drug procurement can take 2-6 weeks depending on the distributor and the approval process. To ensure availability of supplies upon subject enrollment, the Research Pharmacy will procure the initial supply when the clinical trial agreement is executed. This may be prior to any subject screening.
- f. Drug refunds or returns to the supplier are not allowed by the supplier.
- g. Sponsor agrees to pay for total cost of procured drugs, regardless of utilization.
- h. Any expired or unused supply will be shipped back to the sponsor or destroyed per our SOP.

Thank you,

Elnaz Anjom, Pharm.D

Senior Director of Research Pharmacy

Additional Info: Has Project been submitted to IRB?					
Will study be submitted to the Clinical Trials	**				
Anticipated Start Date:	_Approx duration:				
Estimated # of patients					
Monitoring:					
☐Investigator will monitor Research Pharmac	ey function directly without outside monitoring				
□Sponsor will not monitor Research Pharmac	cy function				
□Sponsor will monitor Research Pharmacy f	Tunction				
Monitoring performed by: ☐ Sponsor ☐ CRO/SRO ☐ Other					
Monitoring Company Name/Div					
Monitor Name	Phone				
Fax:E-mai	1:				
The following number of outside monitoring	visits are expected each year				
Effective February 1st, 2022, a new fee sched for all cost estimate requests submitted to the including new studies related to prior ones, su term monitoring. The prior fee schedule will are active prior to February 1st, 2022.	research pharmacy on or after February 1st, ach as studies involving subsequent phases or long-				
be e-mailed to one (1) additional person na	nvestigator for pre-approval. Invoices may also med as Principal Investigator Designee, if vestigator Designee for this protocol, please				
Name of "Principal Investigator Designee"	Email				
The listed " Principal Investigator Designee" will be the point-of-coal of this information changes throughout the duration of study, please					

The Research Pharmacy will not provide services until the signed cost estimate and regulatory documents (IRB approval letter, 1572 form) have been received.

When you are ready to initiate the study, please notify the Research Pharmacist named on the cost estimate.

Thank you.